These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33787591)

  • 21. Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin.
    Weeda ER; Wells PS; Peacock WF; Fermann GJ; Baugh CW; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
    Intern Emerg Med; 2017 Apr; 12(3):311-318. PubMed ID: 27757790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
    Ma G; Zhang R; Wu X; Wang D; Ying K
    Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?
    Coleman CI; Fermann GJ; Weeda ER; Wells PS; Ashton V; Crivera C; Bunz TJ; Wildgoose P; Schein JR; Peacock WF
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):830-837. PubMed ID: 27481875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
    Burness CB; Perry CM
    Drugs; 2014 Feb; 74(2):243-62. PubMed ID: 24430916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Rivaroxaban versus Warfarin for the Treatment of Acute Pulmonary Embolism: A Real-World Study.
    Huang Y; Duan L; He W; Hong C; Guo Y; Wang X; Zhang N; Chen Y; Wang T; Wang J; Liu C
    Anal Cell Pathol (Amst); 2020; 2020():6813492. PubMed ID: 32676276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
    Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
    Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute cytomegalovirus infection associated with pulmonary embolism treated successfully with rivaroxaban: case report.
    de Almeida CMG; Maluf FC; Maluf FC; Gaburo N; Saraceni AF; de Almeida-Neto C
    J Thromb Thrombolysis; 2019 Jan; 47(1):162-164. PubMed ID: 30353451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status.
    Weeda ER; Peacock WF; Fermann GJ; Baugh CW; Wells PS; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
    Int J Clin Pract; 2017 Jan; 71(1):. PubMed ID: 28097761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rivaroxaban for the treatment of venous thromboembolism in real life: A single-center prospective study.
    Demelo-Rodríguez P; Galeano-Valle F; García-Fernández-Bravo I; Piqueras-Ruiz S; Álvarez-Sala-Walther L; Del Toro-Cervera J
    Medicine (Baltimore); 2019 Jan; 98(3):e14093. PubMed ID: 30653127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design.
    Singer AJ; Xiang J; Kabrhel C; Merli GJ; Pollack C; Tapson VF; Wildgoose P; Peacock WF
    Acad Emerg Med; 2016 Nov; 23(11):1280-1286. PubMed ID: 27537530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of the use of rivaroxaban in the length of stay of patients treated for acute venous thromboembolism in a developing country.
    Boietti B; Fili S; Peuchot V; Tabares A; Vázquez F; Gándara E
    Thromb Res; 2021 Aug; 204():143-145. PubMed ID: 33593595
    [No Abstract]   [Full Text] [Related]  

  • 33. A cost-analysis model for anticoagulant treatment in the hospital setting.
    Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
    J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension.
    Wells PS; Prins MH; Levitan B; Beyer-Westendorf J; Brighton TA; Bounameaux H; Cohen AT; Davidson BL; Prandoni P; Raskob GE; Yuan Z; Katz EG; Gebel M; Lensing AWA
    Chest; 2016 Nov; 150(5):1059-1068. PubMed ID: 27262225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
    Kreutz R; Mantovani LG; Haas S; Monje D; Schneider J; Bugge JP; Gebel M; Tamm M; Ageno W; Turpie AGG
    Thromb Res; 2019 Apr; 176():125-132. PubMed ID: 30825694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Utility of Rivaroxaban as Primary Venous Thromboprophylaxis in an Adult Trauma Population.
    Kingdon LK; Miller EM; Savage SA
    J Surg Res; 2019 Dec; 244():509-515. PubMed ID: 31336243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
    Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
    Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reducing length of stay with the direct oral anti-coagulants in low and intermediate risk pulmonary embolism: a single center experience.
    Filopei J; Bondarsky EE; Ehrlich M; Islam M; Bajpayee G; Pang D; Shujaat A; Rowland J; Steiger DJ
    J Thromb Thrombolysis; 2020 Aug; 50(2):399-407. PubMed ID: 31997255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor.
    Gomez D; Razmjou H; Donovan A; Bansal VB; Gollish JD; Murnaghan JJ
    J Arthroplasty; 2017 Mar; 32(3):958-964. PubMed ID: 27843040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.